S-1/A: Shuttle Pharmaceuticals Eyes $16 Million in New Offering to Fuel Cancer Drug Development

Shuttle Pharmaceuticals Holdings seeks to raise capital through a public offering of common stock and warrants to advance its cancer treatment pipeline.

Summary

• Shuttle Pharmaceuticals is planning a public offering to raise up to $16 million through the sale of common stock, pre-funded warrants, and common warrants.
• The offering includes up to 7,207,207 shares of common stock or pre-funded warrants in lieu thereof, along with an equal number of common warrants.
• The assumed public offering price is $1.11 per share or pre-funded warrant and accompanying common warrant, with the exercise price of the common warrants also at $1.11.
• The pre-funded warrants have an exercise price of $0.001 per share and are offered to purchasers who would otherwise exceed beneficial ownership limitations.
• The common warrants are exercisable beginning on the effective date of stockholder approval, or immediately if certain pricing conditions are met, and expire five years from the issuance date.
• A.G.P./Alliance Global Partners and Boustead Securities, LLC are acting as placement agents for the offering, receiving fees totaling 9.0% of the gross proceeds.
• The offering has no minimum amount required to close, and proceeds will be used to fund clinical trials and for general corporate purposes.
• The offering is expected to end no later than November 15, 2024, with the shares underlying the common warrants offered on a continuous basis.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, there are risks associated with the offering and the company's future prospects.

Positives

• The offering will provide capital to advance the clinical development of Ropidoxuridine and other product candidates.
• The pre-funded warrant structure allows certain investors to participate without exceeding ownership limitations.
• The company has flexibility in the use of proceeds, allowing it to adapt to changing business needs.

Negatives

• The offering has no minimum amount required to close, which could result in insufficient funding.
• The placement agents fees will reduce the net proceeds available to the company.
• The offering may dilute existing shareholders ownership.

Risks

• The company may not sell all of the securities offered, resulting in less funding than anticipated.
• The market price of the common stock may decline after the offering.
• There is no established trading market for the warrants, which could limit their liquidity.
• The company is dependent on the success of its clinical trials and regulatory approvals.
• The company faces competition from other pharmaceutical companies.

Future Outlook

The company intends to use the net proceeds from this offering to fund IND-enabling and Phase I and II clinical trials of product candidates, including $2.3 million in payments that will be owed to Theradex Systems, Inc., the clinical research organization (CRO) supporting our Phase II clinical trials for radiation sensitizer Ropidoxuridine. We anticipate that the funds raised from this offering will allow us to complete the Phase II clinical trial, although there is no guarantee that we will not require additional funds.

Industry Context

This announcement comes as the pharmaceutical industry continues to seek innovative funding mechanisms to support drug development, particularly for companies focused on oncology.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees will benefit from the continued funding of the company's operations.
• Patients may benefit from the development of new cancer treatments.

Next Steps

• Complete the public offering.
• Use the proceeds to fund clinical trials and for general corporate purposes.
• Continue to develop and commercialize product candidates.

Key Dates

Keywords

common stock, warrants, public offering, pharmaceuticals, clinical trials, cancer, Ropidoxuridine, pre-funded warrants, placement agents, capital raise